

Josep M Piulats

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4122359/publications.pdf>

Version: 2024-02-01

103
papers

8,595
citations

126907

33
h-index

46799

89
g-index

106
all docs

106
docs citations

106
times ranked

10353
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	30.7	102
2	Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. <i>Cancers</i> , 2022, 14, 782.	3.7	12
3	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. <i>European Urology</i> , 2022, 82, 22-30.	1.9	34
4	Facts and Hopes in Immunotherapy of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4849-4860.	7.0	16
5	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	1.9	17
6	FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1491-1504.	7.0	13
7	Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 80-80.	1.6	0
8	KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)â€”pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)â€”New data after an additional 1 year of follow-up.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	1.6	10
9	Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). <i>Journal of Clinical Oncology</i> , 2021, 39, 586-598.	1.6	117
10	Survival in small choroidal melanocytic lesions with risk factors managed by initial observation until detection of tumour growth. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 251-259.	2.6	1
11	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
12	Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2669.	4.1	22
13	Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes. <i>Journal of Personalized Medicine</i> , 2021, 11, 331.	2.5	2
14	Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, e21513-e21513.	1.6	1
15	Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9531-9531.	1.6	3
16	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9509-9509.	1.6	7
17	CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5086-TPS5086.	1.6	0
18	Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. <i>Oncogene</i> , 2021, 40, 5042-5048.	5.9	2

#	ARTICLE	IF	CITATIONS
19	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	27.0	376
20	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	2.4	22
21	Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. <i>Dermatology and Therapy</i> , 2021, 11, 1777-1790.	3.0	8
22	A single-cell tumor immune atlas for precision oncology. <i>Genome Research</i> , 2021, 31, 1913-1926.	5.5	87
23	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
24	61 Biomarkers of favorable prognosis guides the identification of tumor reactive CD4+ and CD8+ TILs in endometrial cancer. , 2021, 9, A69-A69.		0
25	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1253-1265.	0.7	17
26	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	1.6	450
27	Are antiangiogenics a good "partner" for immunotherapy in ovarian cancer?. <i>Angiogenesis</i> , 2020, 23, 543-557.	7.2	10
28	Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). <i>Journal of Clinical Oncology</i> , 2020, 38, 2916-2925.	1.6	170
29	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	1.6	448
30	Role of POLE and POLD1 in familial cancer. <i>Genetics in Medicine</i> , 2020, 22, 2089-2100.	2.4	76
31	PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. <i>Cancer Management and Research</i> , 2020, Volume 12, 10251-10260.	1.9	5
32	High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. <i>Cancers</i> , 2020, 12, 2950.	3.7	19
33	Sensitivity of cervicovaginal cytology in endometrial carcinoma: A systematic review and meta-analysis. <i>Cancer Cytopathology</i> , 2020, 128, 792-802.	2.4	23
34	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	3.1	32
35	Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 763-766.	1.9	9
36	Lung metastases share common immune features regardless of primary tumor origin. , 2020, 8, e000491.		63

#	ARTICLE	IF	CITATIONS
37	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
38	Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). <i>Cancer Research</i> , 2020, 80, CT014-CT014.	0.9	45
39	Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 104-104.	1.6	4
40	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019, 11, 817.	3.7	11
41	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	3.7	41
42	Defining a mutational signature for endometrial cancer screening and early detection. <i>Cancer Epidemiology</i> , 2019, 61, 129-132.	1.9	7
43	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. <i>Annals of Oncology</i> , 2019, 30, 1370-1380.	1.2	171
44	New perspectives on screening and early detection of endometrial cancer. <i>International Journal of Cancer</i> , 2019, 145, 3194-3206.	5.1	58
45	PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 490-503.	1.6	255
46	Clinical predictors of survival in metastatic uveal melanoma. <i>Japanese Journal of Ophthalmology</i> , 2019, 63, 197-209.	1.9	31
47	Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 408-419.	10.7	276
48	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	3.7	22
49	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	16.8	99
50	Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. <i>Gynecologic Oncology</i> , 2019, 152, 270-277.	1.4	12
51	A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. <i>Human Gene Therapy</i> , 2019, 30, 352-364.	2.7	66
52	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5027-5027.	1.6	7
53	Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5029-5029.	1.6	2
54	Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5086-TPS5086.	1.6	5

#	ARTICLE	IF	CITATIONS
55	KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology, 2019, 37, TPS9598-TPS9598.	1.6	5
56	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 145-145.	1.6	43
57	Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 170-170.	1.6	3
58	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. Journal of Clinical Oncology, 2019, 37, 216-216.	1.6	8
59	Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.. Journal of Clinical Oncology, 2019, 37, 264-264.	1.6	4
60	Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study.. Journal of Clinical Oncology, 2019, 37, 267-267.	1.6	2
61	A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.. Journal of Clinical Oncology, 2019, 37, TPS328-TPS328.	1.6	0
62	Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies. Cancer Research, 2019, 79, 727-727.	0.9	3
63	A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clinical Cancer Research, 2018, 24, 3717-3728.	7.0	267
64	Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clinical Cancer Research, 2018, 24, 3755-3766.	7.0	17
65	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. Pathobiology, 2018, 85, 35-40.	3.8	26
66	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clinical and Translational Oncology, 2018, 20, 57-68.	2.4	17
67	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	1.6	207
68	Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma. Cancer Research and Treatment, 2018, 50, 1130-1139.	3.0	18
69	Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer and Metastasis Reviews, 2018, 37, 335-345.	5.9	23
70	Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. Oncotarget, 2018, 9, 15968-15983.	1.8	15
71	Outcomes of metastatic castration resistant prostate cancer (mCRPC) patients with DNA repair germline mutations (gDDR) following first taxane-based treatment.. Journal of Clinical Oncology, 2018, 36, 247-247.	1.6	0
72	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	7.7	80

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	2.4	12
74	AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1297-1310.	0.7	40
75	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 171-190.	4.4	22
76	Molecular approaches for classifying endometrial carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 200-207.	1.4	137
77	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	1.6	577
78	TGF β 2 Controls Ovarian Cancer Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1658.	4.1	26
79	Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9533-9533.	1.6	13
80	Molecular and clinicopathological classification of high risk endometrial cancer (EC) treated with concurrent chemoradiation therapy (CCT).. <i>Journal of Clinical Oncology</i> , 2017, 35, e17110-e17110.	1.6	0
81	Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma. <i>Eye</i> , 2016, 30, 833-842.	2.1	21
82	Clinical outcomes in metastatic uveal melanoma treated with PD α 1 and PD α L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	4.1	288
83	Immunotherapy in Endometrial Cancer: In the Nick of Time. <i>Clinical Cancer Research</i> , 2016, 22, 5623-5625.	7.0	28
84	Dynamic Change of Polarity in Primary Cultured Spheroids of Human Colorectal Adenocarcinoma and Its Role in Metastasis. <i>American Journal of Pathology</i> , 2016, 186, 899-911.	3.8	34
85	Uveal melanoma as a target for immune-therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 172-172.	1.7	63
86	Pembrolizumab expanded access program (EAP) in Spain: clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21029-e21029.	1.6	0
87	INTRAVITREAL DEXAMETHASONE IMPLANT FOR RADIATION MACULOPATHY SECONDARY TO PLAQUE BRACHYTHERAPY IN CHOROIDAL MELANOMA. <i>Retina</i> , 2015, 35, 1890-1897.	1.7	23
88	ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma. , 2015, 56, 7007.		9
89	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	7.0	36
90	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , 2013, 133, 235-246.	5.1	16

#	ARTICLE	IF	CITATIONS
91	Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. BMC Cancer, 2013, 13, 382.	2.6	21
92	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	27.0	2,412
93	Endoresection Versus Iodine-125 Plaque Brachytherapy for the Treatment of Choroidal Melanoma. American Journal of Ophthalmology, 2013, 156, 334-342.e1.	3.3	28
94	Prostatic sarcoma after conservative treatment with brachytherapy for low-risk prostate cancer. Acta Oncol ³ gica, 2013, 52, 1215-1216.	1.8	8
95	Relative survival of patients with uveal melanoma managed in a single center. Melanoma Research, 2012, 22, 271-277.	1.2	20
96	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Critical Reviews in Oncology/Hematology, 2012, 83, 341-352.	4.4	11
97	Epigenetic disruption of cadherin ¹¹ in human cancer metastasis. Journal of Pathology, 2012, 228, 230-240.	4.5	60
98	Metastatic uveal melanoma. Melanoma Research, 2011, 21, 217-222.	1.2	46
99	Uveal Melanoma and <i>BRCA1</i> / <i>BRCA2</i> Genes: A Relationship That Needs Further Investigation. Journal of Clinical Oncology, 2011, 29, e827-e829.	1.6	22
100	Serum and Tissue Profiling in Bladder Cancer Combining Protein and Tissue Arrays. Journal of Proteome Research, 2010, 9, 164-173.	3.7	30
101	Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research, 2009, 15, 3384-3395.	7.0	57
102	Discovery of myopodin methylation in bladder cancer. Journal of Pathology, 2008, 216, 111-119.	4.5	27
103	Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study. Journal of Clinical Oncology, 2008, 26, 5416-5421.	1.6	117